Efficacy of etanercept in the tumor necrosis factor receptor–associated periodic syndrome: A prospective, open‐label, dose‐escalation study

Abstract

Etanercept reduces symptoms and serum levels of inflammatory markers of TRAPS in a dose-dependent manner, but does not completely normalize symptoms or acute-phase reactant levels. Although long-term adherence to etanercept is poor, continuing to receive etanercept may provide continued symptomatic benefit.